Articles from Axcelead Drug Discovery Partners, Inc.

xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research collaboration aimed at developing RNA structure-targeted small molecule therapeutics for multiple diseases.

Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets.

Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Chuo-Ku, Tokyo, Japan; “Astellas”) to explore new candidate compounds for targeted protein degraders.

Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announced on September 10 that it had entered into a Master Service Agreement with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to support their goal of discovering and developing innovative and novel medicines to help address unmet medical needs.

Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced on September 5 that it has entered into a strategic research and collaboration agreement with Eli Lilly and Company (“Lilly”) for multiple drug discovery programs.